Lenox Wealth Management’s Ascendis Pharma A/S ASND Stock Holding History

Lenox Wealth Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	$927K	Buy	+6,273	New	+$861K	0.28%	73

Other funds holding ASND

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Lenox Wealth Management's ASND Position: Q2 2020 in Review

Lenox Wealth Management opened a new position in Ascendis Pharma A/S (ASND) in Q2 2020: 6,273 shares worth $927K. The stake represents 0.28% of the portfolio and ranks #73 among its holdings.

154 funds tracked by Wall St. Rank hold ASND as of Q2 2020.

Lenox Wealth Management held 6,273 shares of Ascendis Pharma A/S worth $927K as of Q2 2020.
Ascendis Pharma A/S was a new Lenox Wealth Management position in Q2 2020.
Ascendis Pharma A/S made up 0.28% of Lenox Wealth Management's portfolio in Q2 2020, its #73 holding.
154 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2020.

Based on Lenox Wealth Management's 13F filing for Q2 2020, filed 28 Jul 2020.